Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Aim: To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with non-infectious uveitis (NIU), refractory to conventional immunomodulatory therapy (IMT).
Methods: Prospective, noncomparative, interventional case series. Five patients with bilateral panuveitis (four post-therapeutic vitrectomy) and persistent intraocular inflammation on conventional IMT for > 2 years received three doses of subconjunctival adalimumab 5 mg/0.1 mL at two-week intervals and followed up for 24 weeks.
Results: No cases of persistent conjunctival congestion, corneal erosions or infection, or intraocular pressure > 21 mmHg were noted. Improvement in inflammatory scores and best-corrected visual acuity (BCVA) were noted in three patients each and worsening in none. None of the three patients who showed initial improvement in visual acuity had any baseline cystoid macular edema or vitreous haze to account for the improvement in BCVA.
Conclusion: Subconjunctival administration of 5 mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/09273948.2025.2512170 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.
Ocul Immunol Inflamm
May 2025
Massachusetts Eye and Ear Infirmary & Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts, USA.
Aim: To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with non-infectious uveitis (NIU), refractory to conventional immunomodulatory therapy (IMT).
Methods: Prospective, noncomparative, interventional case series. Five patients with bilateral panuveitis (four post-therapeutic vitrectomy) and persistent intraocular inflammation on conventional IMT for > 2 years received three doses of subconjunctival adalimumab 5 mg/0.
The prophylactic value of TNF-α inhibitors against retinal cell apoptosis and optic nerve axon loss after corneal surgery or trauma.
Acta Ophthalmol
May 2024
Massachusetts Eye and Ear, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA.
Article Synopsis
- Late secondary glaucoma is a serious condition that can develop after surgeries, injuries, or infections, largely driven by TNF-α, which triggers cell death in the retina and damage in the optic nerve.
- The study tested the safety and effectiveness of two TNF-α inhibitors, adalimumab and infliximab, on rabbits, assessing both how well the drugs were tolerated and their ability to protect retinal cells after induced damage.
- Results showed that low doses of adalimumab and infliximab were safe and effective, with 4.0 mg of adalimumab providing strong protection against cell death shortly after injury.
Sustained Inhibition of VEGF and TNF-α Achieves Multi-Ocular Protection and Prevents Formation of Blood Vessels after Severe Ocular Trauma.
Pharmaceutics
July 2023
Department of Ophthalmology, Harvard Medical School, Boston, MA 02115, USA.
Article Synopsis
- - This study developed a practical therapy using a thermosensitive drug delivery system (DDS) to treat ocular injuries, specifically delivering TNF-α and VEGF inhibitors to aid in eye recovery.
- - In tests on Dutch-belted pigmented rabbits, the dual DDS led to sustained delivery of drugs over three months, resulting in significant improvements in corneal healing, reduced immune cell infiltration, and prevention of nerve cell loss compared to control treatments.
- - The results showed that the combination therapy effectively inhibited corneal neovascularization, accelerated healing, and was safe for use, demonstrating the potential for this method in clinical applications for ocular protection post-injury.
Frequency and Treatment Regimens of Macular Edema in 1946 Consecutive Patients with Noninfectious Uveitis at a Tertiary Ophthalmic Center in Shaanxi, China.
Ophthalmol Ther
October 2023
Shaanxi Eye Hospital, Xi'an People's Hospital (Xi'an Fourth Hospital), Affiliated People's Hospital of Northwest University, No 21, Jiefang Road, Xi'an, 710004, Shaanxi, China.
Article Synopsis
- The study examined the occurrence of uveitic macular edema (UME) among 1,946 patients with various forms of noninfectious uveitis at a specialized eye clinic in Shaanxi Province, China.
- Out of the total patients, 6.89% experienced UME, with the average age of affected individuals being 47.33 years.
- Treatment methods for UME included adalimumab combined with prednisone, interferon-α2a, corticoid injections, and other medications, highlighting the diverse approaches used to manage this condition.
Effect of adalimumab on experimental corneal neovascularization model.
Int Ophthalmol
June 2023
Department of Ophthalmology, Faculty of Medicine, Süleyman Demirel University, 32260, Isparta, Turkey.
Article Synopsis
- - The study aimed to assess the effectiveness of adalimumab (ADA) in preventing corneal neovascularization (CNV) and to compare its results with those of bevacizumab (BEVA) in a rat model.
- - Twenty-four female Winstar rats were divided into six groups, receiving different treatments, with evaluations occurring five days post-treatment using various staining techniques to analyze histopathological changes.
- - Results indicated that both ADA and BEVA were successful in reducing CNV, but ADA was found to be more effective than BEVA in reducing vascular endothelial growth factor (VEGF) expression, highlighting the need for further research on these treatments.